Acutus Medical (OTCPK:AFIB) - Aandelenkoers, Nieuws & Analyse

AFIB Overzicht aandelen

Acutus Medical, Inc. ontwerpt, produceert en verkoopt verschillende instrumenten voor ablatieprocedures op basis van katheter voor de behandeling van verschillende ritmestoornissen in de Verenigde Staten en daarbuiten.

Over het bedrijf

AFIB fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( $2M )

Negatief eigen vermogen

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Acutus Medical, Inc. Concurrenten

Biomerica

NasdaqCM:BMRA

US$6.6m

ReShape Lifesciences

NasdaqCM:RSLS

US$2.8m

Venus Concept

NasdaqCM:VERO

US$3.0m

Talis Biomedical

OTCPK:TLIS

US$3.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Acutus Medical
Historische aandelenkoersen
Huidige aandelenkoers	US$0.08
52 Week Hoogtepunt	US$0.43
52 Week Laag	US$0.025
Bèta	0.013
11 maand verandering	-49.91%
3 maanden verandering	110.82%
1 Jaar Verandering	-59.97%
33 jaar verandering	-97.85%
5 jaar verandering	n/a
Verandering sinds IPO	-99.70%

Recent nieuws en updates

Recent updates

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Feb 24

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Dec 20

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Jul 18

Acutus files for FDA approval of catheter ablation system AcQBlate

Oct 18

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Aug 11

Acutus Medical sees Q2 revenue above consensus estimate

Jul 21

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Apr 06

Analysts Have Been Trimming Their Acutus Medical, Inc. (NASDAQ:AFIB) Price Target After Its Latest Report

May 15

Rendement voor aandeelhouders

	AFIB	US Medical Equipment	US Markt
7D	-48.0%	2.0%	5.7%
1Y	-60.0%	29.9%	36.9%

Rendement versus industrie: AFIB presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 29.9 % opleverde.

Rendement versus markt: AFIB presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 36.9 % opleverde.

Prijsvolatiliteit

Is AFIB's price volatile compared to industry and market?
AFIB volatility
AFIB Average Weekly Movement	41.1%
Medical Equipment Industry Average Movement	7.9%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van AFIB is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van AFIB is het afgelopen jaar gestegen van 31% naar 41%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	232	Takeo Mukai	www.acutusmedical.com

Acutus Medical, Inc. ontwerpt, produceert en verkoopt verschillende hulpmiddelen voor kathetergebaseerde ablatieprocedures voor de behandeling van verschillende ritmestoornissen in de Verenigde Staten en daarbuiten. Het productassortiment omvat nieuwe toegangskokers, transseptale doorgangshulpmiddelen, diagnostische en mapping katheters, conventionele en contactablatiekatheters en mapping- en beeldvormingsconsoles en accessoires, evenals ondersteunende algoritmen en softwareprogramma's. Acutus Medical, Inc. werd opgericht in 2011 en heeft zijn hoofdkantoor in Carlsbad, Californië.

Acutus Medical, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Acutus Medical zich tot de beurswaarde?
AFIB fundamentele statistieken
Marktkapitalisatie	US$2.44m
Inkomsten(TTM)	-US$5.82m
Inkomsten(TTM)	US$12.16m

0.2x

P/S-verhouding

-0.4x

Koers/Winstverhouding

Is AFIB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AFIB resultatenrekening (TTM)
Inkomsten	US$12.16m
Kosten van inkomsten	US$13.79m
Brutowinst	-US$1.63m
Overige uitgaven	US$4.19m
Inkomsten	-US$5.82m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.20
Brutomarge	-13.40%
Nettowinstmarge	-47.89%
Schuld/Eigen Vermogen Verhouding	-669.8%

Hoe presteerde AFIB op de lange termijn?

Bekijk historische prestaties en vergelijking

AFIB Overzicht aandelen

Beloningen

Risicoanalyse

Acutus Medical, Inc. Concurrenten

NasdaqCM:BMRA

US$6.6m

NasdaqCM:RSLS

US$2.8m

NasdaqCM:VERO

US$3.0m

OTCPK:TLIS

US$3.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Nasdaq Files A Form 25 Notification of Delisting with the Securities and Exchange Commission to Complete Acutus Medical, Inc.'s Delisting

Acutus Medical, Inc.(NasdaqCM:AFIB) dropped from NASDAQ Composite Index

Acutus Medical Provides Non-Compliance Update

Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Recent updates

Nasdaq Files A Form 25 Notification of Delisting with the Securities and Exchange Commission to Complete Acutus Medical, Inc.'s Delisting

Acutus Medical, Inc.(NasdaqCM:AFIB) dropped from NASDAQ Composite Index

Acutus Medical Provides Non-Compliance Update

Acutus Medical, Inc., Annual General Meeting, Jun 13, 2024

New minor risk - Shareholder dilution

New major risk - Negative shareholders equity

Full year 2023 earnings released: US$0.41 loss per share (vs US$1.40 loss in FY 2022)

Investors Give Acutus Medical, Inc. (NASDAQ:AFIB) Shares A 29% Hiding

Acutus Medical, Inc. Announces Board Changes

Market Cool On Acutus Medical, Inc.'s (NASDAQ:AFIB) Revenues Pushing Shares 43% Lower

Acutus Medical, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.72 loss in 3Q 2022)

Acutus Medical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acutus Medical Receives A Letter from Nasdaq Approving the Company’s Application to List Its Securities on the Nasdaq Capital Market

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Take Care Before Diving Into The Deep End On Acutus Medical, Inc. (NASDAQ:AFIB)

Acutus Medical, Inc. Announces Executive Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Year 2023

Acutus Medical Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical, Inc. Announces Results from the AcQForce Flutter Study “AcQForce Flutter: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter”

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$4.13

Acutus Medical Achieves Eu Mdr Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic

Acutus Medical, Inc. Announces Full Market Release of Next Generation Software Platform AcQMap 8.5

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations

Acutus Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Acutus Medical Receives Non-Compliance Notice From Nasdaq

High number of new directors

Acutus Medical, Inc. Announces Submission of Premarket Approval Application for AcQBlate Force Sensing Ablation Catheter & System

Acutus files for FDA approval of catheter ablation system AcQBlate

Glancy Prongay & Murray LLP Appoints Lead Counsel in Securities Class Action Against Acutus Medical, Inc

Acutus Medical, Inc. Announces Board Changes

Consensus forecasts updated

Price target increased to US$3.38

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Acutus Medical Non-GAAP EPS of -$0.93 misses by $0.17, revenue of $4.1M beats by $0.13M

Acutus Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

Acutus Medical, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Acutus Medical sees Q2 revenue above consensus estimate

Acutus Medical, Inc. announced that it has received funding from Deerfield Management Company, L.P. Series C

Medtronic plc (NYSE:MDT) completed the acquisition of Left-heart Access Portfolio from Acutus Medical, Inc. (NasdaqGS:AFIB).

Acutus Medical, Inc. Announces FDA Clearance, Commercial Launch of AcQCross Line Extension Compatible with Watchman Delivery System

Acutus Medical Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

Acutus Medical, Inc. Completes Enrollment in Ide Trial with Its Acqblate® Force Sensing Ablation System

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$3.50

High number of new directors

Price target decreased to US$4.00

Acutus Medical, Inc. (NASDAQ:AFIB) Analysts Just Trimmed Their Revenue Forecasts By 25%

Consensus revenue estimates fall by 25%

Full year 2021 earnings: EPS exceeds analyst expectations

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Acutus Medical, Inc